Filtered By:
Specialty: Neurology
Condition: Allergy
This page shows you your search results in order of date. This is page number 3.
Order by Relevance | Date
Total 65 results found since Jan 2013.
A Phase III randomized, double-blind, placebo-controlled study to assess the efficacy and safety of abobotulinumtoxinA (Dysport(R)) in adults with upper limb spasticity (S28.001)
CONCLUSIONS: In this large-scale study, abobotulinumtoxinA improved muscle tone, spasticity and movement. Standardization of scales in this clinical study, particularly those less used (e.g. Tardieu) has the potential to improve the management of patients affected by spasticity after stroke/TBI. Study Supported by: IpsenDisclosure: Dr. Brashear has received personal compensation for activities with Allergan and Concerta as a consultant. Dr. Brashear has received royalty payments from books. Dr. Brashear has received research support from Ipsen, Merz, Allergan and NINDS. Dr. Marciniak has received personal compensation for ...
Source: Neurology - April 8, 2015 Category: Neurology Authors: Brashear, A., Marciniak, C., Edgley, S., Gul, F., Hedera, P., McAllister, P., O'Dell, M., Rubin, B., Heather, W., Vilain, C., Picaut, P., Gracies, J.-M. Tags: Neuro-rehabilitation Source Type: research
Topline results from a randomized, placebo-controlled, Phase III study investigating the safety and efficacy of incobotulinumtoxinA in treating post-stroke spasticity of the upper limb (S28.002)
CONCLUSIONS: 400 U IncobotulinumtoxinA is effective and well tolerated for combined treatment of 3 target patterns (flexed elbow; flexed wrist; clenched fist) in ULS. Study Supported by: Merz North America, Inc.Disclosure: Dr. Sethi has received personal compensation for activities with Synosia, Lundbeck Research USA, Inc., Auspex Pharmaceuticals, Veloxis Pharmaceuticals, Adamas Pharmaceuticals, Impax Laboratories, Teva Neuroscience, and US WorldMeds as a consultant and/or Dr. Elovic has received personal compensation for activities with Allergan, Inc. and Solstice Neurosciences. Dr. Munin has received research support fro...
Source: Neurology - April 8, 2015 Category: Neurology Authors: Sethi, K., Elovic, E., Munin, M., Marciniak, C., Hiersemenzel, R., Hanschmann, A. Tags: Neuro-rehabilitation Source Type: research
Using a Delphi Panel to Identify a Treatment Paradigm for Injecting Botulinum Toxin to Treat Common Postures in Post-Stroke Upper Limb Spasticity (P5.167)
CONCLUSIONS: The modified Delphi panel provided consensus on 3 aggregate common upper-limb postures associated with PSS and corresponding treatment paradigms for injecting onabotulinumtoxinA. Study Supported by: Allergan Disclosure: Dr. Simpson has received personal compensation for activities with NeurogesX, Eli Lilly & Company, AstraZeneca, Allergan, Inc., ViroMed, Pfizer Inc., Astellas Pharma, Ipsen, and Merz Pharma as a consultant and/or speaker. Dr. Patel has received personal compensation for activities with Allergan, Inc. as an advisory board member. Dr. Alfaro has received personal compensati...
Source: Neurology - April 8, 2015 Category: Neurology Authors: Simpson, D., Patel, A., Alfaro, A., Ayyoub, Z., Charles, D., Dashtipour, K., Esquenazi, A., Graham, G., McGuire, J., Odderson, I. Tags: Cerebrovascular Disease and Interventional Neurology: Recovery and Rehabilitation Source Type: research
Regular aspirin use does not reduce risk of incident cognitive decline (P7.117)
CONCLUSIONS: Regular aspirin did not provide a protective association against incident cognitive impairment in a large, biracial, and geographically diverse cohort. Study Supported by: This research project is supported by a cooperative agreement U01 NS041588 from the National Institute of Neurological Disorders and Stroke, National Institutes of Health, Department of Health and Human Service. Disclosure: Dr. Kelley has received personal compensation for activities with Eli Lilly & Co. as a consultant. Dr. McClure has received research support from Genzyme and Amgen. Dr. Unverzagt has received personal compensation...
Source: Neurology - April 8, 2015 Category: Neurology Authors: Kelley, B., McClure, L., Unverzagt, F., Kissela, B., Kleindorfer, D., Howard, G., Wadley, V. Tags: Aging, Dementia, Cognitive, and Behavioral Neurology: Cardio- and Cerebrovascular Factors in Dementia Source Type: research
Intravenous Tissue Plasminogen Activator Treatment for Acute Ischemic Stroke in the REGARDS Study (P7.138)
CONCLUSIONS:Our study of unselected US hospitals showed low tPA utilization. Documented reasons for non-use were suboptimal with the lowest among patients not evaluated by a stroke team. Our sample was not limited to hospitals participating in national quality improvement programs, thus increasing generalizability. Strategies that focus on earlier hospital arrival and educating both the public and healthcare field to increase tPA utilization are urgently needed.Disclosure: Dr. Sands has nothing to disclose. Dr. Albright has nothing to disclose. Dr. Blackburn has nothing to disclose. Dr. Boehme has nothing to disclose. Dr. ...
Source: Neurology - April 8, 2015 Category: Neurology Authors: Sands, K., Albright, K., Blackburn, J., Boehme, A., Howard, G., Howard, V., Judd, S., Kissela, B., Limdi, N., Rhodes, D., Shiue, H., Sisson, A., Safford, M. Tags: Cerebrovascular Disease and Interventional Neurology: Race, Ethnicity, and Stroke Source Type: research
Urticarial allergic reaction to alteplase: A case report (P6.243)
CONCLUSIONS: Physicians treating acute ischemic stroke with alteplase should be aware of this uncommon but potentially dangerous complication in the spectrum of anaphylactic reactions.Disclosure: Dr. Papolin has nothing to disclose. Dr. Mendes has nothing to disclose. Dr. Lange has nothing to disclose. Dr. Germiniani has nothing to disclose. Dr. Harger has nothing to disclose. Dr. Zetola has nothing to disclose. Dr. Chamma has nothing to disclose.
Source: Neurology - April 8, 2015 Category: Neurology Authors: Papolin, L., Mendes, D., Lange, M., Germiniani, F., Harger, R., Zetola, V., Chamma, J. Tags: Cerebrovascular Disease and Interventional Neurology: Thrombolysis Complications Source Type: research
An Unusual Case Of Cadasil With Occipital Lobe Involvement (P6.006)
CONCLUSION: We discuss the unique features of a rare case of occipital lobe predominant CADASIL lacking the typical anterior temporal lobe involvement. This case exemplifies the heterogeneity of clinical findings that may be associated with NOTCH3 mutations.Disclosure: Dr. Mishra has nothing to disclose. Dr. Rao has nothing to disclose. Dr. Flippen has received personal compensation for activities with MAP Pharmaceuticals/Allergan. Dr. Flippen has received personal compensation in an editorial capacity for the Journal of Graduate Medical Education and Up-To-Date. Dr. Flippen has received Dr. Fogel has received personal com...
Source: Neurology - April 8, 2015 Category: Neurology Authors: Mishra, S., Rao, N., Flippen, C., Fogel, B., Hathout, G., Thomas, M., Kattan, J., Trikamji, B. Tags: Treatments, Therapeutics, and Biomarkers Poster Discussion Session Source Type: research
Temporal Trends of Emergency Department Arrival Times after Acute Ischemic Stroke: a Population-Based Study (S21.006)
CONCLUSIONS: We found that IS patients arrived at progressively later times from 1993/4-2010. More research is needed to determine the reasons for delayed arrival to medical attention, since time from onset dominates the exclusion of patients from rt-PA. Study Supported by: Disclosure: Dr. Katz has nothing to disclose. Dr. Khoury has nothing to disclose. Dr. Alwell has nothing to disclose. Dr. Moomaw has received research support from the National Institutes of Health. Dr. Kissela has received personal compensation for activities with Allergan, Inc., AbbVie, and Reata Pharmaceuticals. Dr. Flaherty has received personal com...
Source: Neurology - April 8, 2015 Category: Neurology Authors: Katz, B., Khoury, J., Alwell, K., Moomaw, C., Kissela, B., Flaherty, M., Woo, D., Adeoye, O., Khatri, P., Ferioli, S., Mackey, J., Martini, S., De Los Rios La Rosa, F., Kleindorfer, D. Tags: Cerebrovascular Disease and Interventional Neurology: Prehospital and Acute Ischemic Stroke Treatment Source Type: research
The BioFIND Study (Fox Investigation For New Discovery Of Biomarkers In Parkinson's Disease): Design And Methodology (P4.043)
CONCLUSIONS:The BioFIND study will provide a valuable biospecimen resource for the discovery and validation of novel biomarkers in typical, moderate to advanced PD. Promising markers can then be verified in longitudinal cohorts and more heterogeneous PD subjects.Study Supported by:This study is sponsored by MJFF with support from NINDS. We also thank supports from NIH CTSA (RNA).Disclosure: Dr. Kang has received personal compensation for activities with Caremark Inc. as a medical advisory board member. Dr. Kang has received research support from Allergan, Inc. Dr. Alcalay has received personal compensation for activities w...
Source: Neurology - April 9, 2014 Category: Neurology Authors: Kang, U., Alcalay, R., Goldman, J., Henchcliffe, C., Hogarth, P., Tuite, P., Xie, T., Frasier, M., Kopil, C., Vincent, L., Willis, N., Casaceli, C., Rudolph, A. Tags: Movement Disorders: Parkinson ' s Disease Biomarkers Source Type: research
OSA Is Under-Reported In Patients Admitted With Acute Stroke (P5.280)
CONCLUSION: The prevalence of OSA as a secondary diagnosis of those admitted with stroke was less than 1/3 that which would be predicted based on community prevalence. Since OSA is felt to be a risk factor for stroke, better detection of OSA in patients admitted for stroke is needed.Disclosure: Dr. Shorten has nothing to disclose. Dr. Dubinsky has received personal compensation for activities with Allergan Inc. Dr. Dubinsky has received research support from Allergan Inc., Medevation Pharmaceuticals, and from the National Institutes of Health.
Source: Neurology - April 9, 2014 Category: Neurology Authors: Shorten, S., Dubinsky, R. Tags: Sleep: Sleep Related Breathing Source Type: research
Is Intracranial Arterial Involvement A Subgroup of Neuro-Behcet Syndrome? (P5.035)
Conclusion:Neurological involvement in BS patients is generally due to venous inflammation. Intracranial arterial involvement in NBS is rare, but it should be kept in mind that it can occur during the course of the disease independent of other stroke risk factors.Disclosure: Dr. Zeydan has nothing to disclose. Dr. Uygunoglu has received personal compensation for activities with Merck Serono, Biogen Idec, Novartis and Allergan Inc. as an attendee at congresses or symposia. Dr. Tutuncu has nothing to disclose. Dr. Yalcinkaya has nothing to disclose. Dr. Altintas has received personal compensation for activities with The Scie...
Source: Neurology - April 9, 2014 Category: Neurology Authors: Zeydan, B., Uygunoglu, U., Tutuncu, M., Yalcinkaya, C., Altintas, A., Saipoglu, S., Siva, A. Tags: General Neurology IV Source Type: research
Satisfaction With Botulinum Toxin Treatment In Post-Stroke Spasticity: Results From Two Cross-Sectional Surveys Of Patients And Physicians (P1.143)
CONCLUSIONS: Overall, patient satisfaction with botulinum toxin treatment for post-stroke spasticity is high, but declines toward the end of each injection cycle. Hence, many patients would prefer shorter injection intervals than the standard 12 weeks. While most physicians are satisfied with botulinum toxin injections for post-stroke spasticity, many feel that a proportion of patients might gain additional benefit from shorter intervals and higher doses than those currently permitted.Study Supported by: Merz Pharmaceuticals GmbHDisclosure: Dr. Bensmail has received personal compensation for activities with Merz Pharma, Ip...
Source: Neurology - April 9, 2014 Category: Neurology Authors: Bensmail, D., Hanschmann, A. Tags: Cerebrovascular Disease and Interventional Neurology: Rehabilitation and Recovery Source Type: research
A Compilation of Spasticity Studies Evaluating Onabotulinumtoxin A (P3.042)
CONCLUSIONS: OnabotulinumtoxinA has been extensively studied for treatment of spasticity against a variety of rating scales/assessments and outcomes measures.Study Sponsored by: Allergan, Inc.Disclosure: Dr. Patel has received personal compensation for activities with Allergan Inc. Dr. Manack has received personal compensation for activities with Allergan Inc.
Source: Neurology - April 9, 2014 Category: Neurology Authors: Patel, P., Manack, A. Tags: Neural Repair and Neuro-rehabilitation: Clinical Source Type: research
Gender and Dopaminergic Medication Treatment in Early Parkinson Disease (P3.069)
CONCLUSIONS: Although we did not observe gender differences in the type and dose of dopaminergic treatment in LS-1 participants with early PD, further research is needed to evaluate gender influences on dopaminergic medication treatment in mid- and late-stage PD.Study Supported by: on behalf of the NET-PD LS1 investigators.Disclosure: Dr. Umeh has nothing to disclose. Dr. Pérez has nothing to disclose. Dr. Augustine has nothing to disclose. Dr. Dhall has received personal compensation for activities with UCP Pharma, Impax Pharmaceuticals, and Teva Neuroscience. Dr. Dewey has received personal compensation for activi...
Source: Neurology - April 9, 2014 Category: Neurology Authors: Umeh, C., Perez, A., Augustine, E., Dhall, R., Dewey, R., Mari, Z., Simon, D., Wills, A. M., Christine, C., Schneider, J., Suchowersky, O. Tags: Movement Disorders: Clinical Features of Parkinson ' s Disease Source Type: research
Vascular Parkinsonism in a Tertiary Care Stroke Prevention Clinic: Prevalence and Development of a New Screening Strategy (P3.087)
CONCLUSIONS: We documented a prevalence of 4.7% for VasP in a tertiary care SPC. The TQ had a high sensitivity and specificity to screen for Parkinsonism when the cut off 蠅4 was used. The FMAS was helpful to confirmVasP and distinguish it from the other forms of parkinsonism, including IPD. The two-step TQ-FMAS screening might be a useful strategy to identify promptly patients with VasP.Study Supported by: the Toupin Foundation.Disclosure: Dr. Manosalva Alzate has nothing to disclose. Dr. Jeerakathil has nothing to disclose. Dr. Saqqur has nothing to disclose. Dr. Camicioli has nothing to disclose. Dr. Suchowersky h...
Source: Neurology - April 9, 2014 Category: Neurology Authors: Manosalva Alzate, H., Jeerakathil, T., Saqqur, M., Camicioli, R., Suchowersky, O. Tags: Movement Disorders: Other Parkinsonian Disorders Source Type: research
